02:56 , Nov 21, 2014 |  BC Extra  |  Financial News

BioNano raises $53M in series C

BioNano Genomics Inc. (San Diego, Calif.) raised $53 million in an untranched series C round led by new investors Legend Capital and Novartis Venture Fund. Other new investors included Federated Kaufmann Fund and Monashee Investment...
07:00 , Oct 7, 2013 |  BC Week In Review  |  Financial News

BioNano Genomics completes venture financing

BioNano Genomics Inc. , San Diego, Calif.   Business: Diagnostic, Genomics, Supply/Service   Date completed: 10/2/13   Type: Venture financing   Raised: $10 million   Investors: Battelle Ventures; Domain Associates; Gund Investment  ...
07:00 , Jul 16, 2012 |  BC Week In Review  |  Financial News

BioNano Genomics completes venture financing

BioNano Genomics Inc. , San Diego, Calif.   Business: Diagnostic, Genomics, Supply/Service   Date completed: 6/29/12   Type: Venture financing   Raised: $10 million   Investors: Battelle Ventures; Domain Associates; Gund Investment; Innovation Valley Partners...
00:36 , Mar 18, 2011 |  BC Extra  |  Financial News

BioNanomatrix raises $23.3 million

BioNanomatrix Inc. (Philadelphia, Pa.) raised $23.3 million in a series B round led by Domain Associates. New investor Gund Investment joined existing investors Battelle Ventures; Innovation Valley Partners; and KT Venture Group in the round....
07:00 , Apr 5, 2010 |  BC Week In Review  |  Clinical News

NellOne preclinical data

In mouse cardiomyocytes in vitro, the Nell1 protein provided significant protection and prevented cell death upon exposure to a hypoxic environment vs. control mice treated with the nitric oxide (NO) synthase inhibitor L-monomethylarginine. NellOne has...
07:00 , Apr 5, 2010 |  BC Week In Review  |  Clinical News

NellOne preclinical data

In a diabetic mouse model of skeletal muscle wound, Nell1 protein significantly increased new blood vessel formation and muscle growth vs. untreated control mice. NellOne has an exclusive, worldwide license to patents covering the gene...
08:00 , Feb 8, 2010 |  BC Week In Review  |  Company News

NellOne, U.S. Department of Energy deal

NellOne received an exclusive, worldwide license to patents covering the gene encoding NEL-like protein 1 (NELL1) , a protein kinase C (PKC) beta binding protein from DOE's Oakridge National Laboratory. Further terms were not disclosed....
01:35 , Jul 25, 2008 |  BC Extra  |  Financial News

NuPathe raises $30 million

NuPathe (Conshohocken, Pa.) raised $30 million in a series B round led by Quaker BioVentures and SR One. Previous investors Safeguard Scientifics; Bay City Capital/Birchmere Ventures; Battelle Ventures; and BioAdvance Ventures also participated in the...
07:00 , Jun 9, 2008 |  BC Week In Review  |  Company News

Battelle Ventures L.P., U.S. Department of Energy cardiovascular news

Battelle Ventures formed regenerative medicine company NellOne Therapeutics Inc. to develop protein therapeutics to repair damaged heart tissue. The therapeutics will be based on the discovery by the DoE's Oakridge National Laboratory that NEL-like protein...
00:53 , Jun 5, 2008 |  BC Extra  |  Company News

Battelle Ventures spins out NellOne

Battelle Ventures (Princeton, N.J.) formed NellOne Therapeutics (Knoxville, Tenn,), a regenerative medicine company spun out of the U.S. Department of Energy's Oak Ridge National Laboratory. The newco will focus on developing protein therapeutics that can...